Interestingly, we observed that Tregs Foxp3 [MFI in CD4+] and Foxp3 [MFI in CD4+ CD25+ CD127-] showed a significant increase in the early MASLD group as compared to the control group (p=0.02, p=0.005, respectively), which we did not notice in a group of advanced MASLD patients (Table 2). Here, FOXP3 is linked to metabolic dysfunction-associated steatotic liver disease.